BioSpace News Archive

Centers for Medicare and Medicaid Services Accepts Myomo’s Application to Classify the MyoPro ® as a Brace.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million at-the-market from select existing investors, primarily to fund initiation of the Company’s launch preparations in anticipation of the EB-101 Biologics License Application (BLA) submission and potential approval.

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier today, all resolutions were duly passed on a show of hands.

Camena Bioscience announced it has closed a $10m Series A financing round, led by Mercia.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has completed the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial management, patient access and technology solutions to pharmaceutical and biotechnology organizations around the world.

Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.

Nevakar Injectables Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has approved its new drug application (“NDA”) for Cyclophosphamide Injection, 200mg/mL vials for use in combination therapy for various types of cancers, including malignant lymphoma, multiple myeloma, and various types of leukemia.

DiaCarta, Ltd. today announced the termination of its Business Combination Agreement with HH&L Acquisition Co.

The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023: Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.